Vanishing bile duct syndrome: causes, diagnosis and treatment

Bile is a liquid made in the liver to help digest fats and remove waste. The NHS explains that it passes out of the liver through small tubes called bile ducts. In vanishing bile duct syndrome (VBDS) the small ducts inside the liver are lost. A case report in the ACG Case Reports Journal describes it as an acquired liver disease characterised by the progressive destruction and loss of intrahepatic bile ducts, which frequently signifies end-stage cholestatic liver disease. A second review calls it a rare condition leading to cholestasis and ductopenia.

The term ductopenia simply means a shortage of bile ducts. When there are too few ducts, bile builds up in the liver and the bloodstream, a state called cholestasis. VBDS is best seen as a common end point reached by many different routes, which is why finding the underlying cause is the central task.

It is not the same as primary biliary cholangitis, in which the NHS says the immune system mistakenly attacks the bile ducts. Primary biliary cholangitis is one of the autoimmune diseases that has to be excluded when VBDS is suspected.

The symptoms are those of cholestasis. The NHS lists jaundice, which is when your skin or the whites of your eyes turn yellow, and says you may also have itchy skin, darker pee and paler poo than usual. Case reports describe people presenting with jaundice, itching, abdominal discomfort and fever, with blood tests showing high bilirubin and a raised alkaline phosphatase.

In the related cholestatic condition primary biliary cholangitis, the NHS lists fatigue, itchy skin and, at an advanced stage, vitamin deficiencies (A, D, E and K) among the problems, and similar effects can be expected whenever bile flow is poor. A published report notes that irreversible bile duct loss in unrelenting liver injury may result in extensive ductopenia and secondary biliary cirrhosis.

The published literature lists a wide range of causes: congenital and genetic diseases, autoimmune conditions, cancers and infections. Medicines are a recognised trigger, and the reports name common antibiotics such as levofloxacin, meropenem, amoxicillin and azithromycin as having been associated with it. Other associations include graft-versus-host disease after transplant, ischaemic conditions of the biliary tree, and bacterial, viral and parasitic infections.

Cancer can be part of the picture. Hodgkin lymphoma is a recognised association, and in one case report VBDS was the presenting feature before the lymphoma was found, improving after the lymphoma was treated. In some people no cause is found. The report calls this idiopathic adulthood ductopenia and says it has a poor prognosis, with liver failure occurring in up to 50% of patients.

Because medicines are such a common trigger, an accurate history of all prescribed, over-the-counter and herbal products is essential. Never stop a prescribed medicine without advice from the prescriber, but do mention jaundice or itching promptly.

The first step in the NHS is blood tests, including liver function tests, and a liver ultrasound. The NHS notes that for primary biliary cholangitis an ultrasound scan helps to rule out other problems with your bile ducts, and the same principle applies here. Imaging often looks normal, because the affected ducts are very small. The case report says the small ductules measure less than 15 micrometres, so scans may fail to provide a diagnosis.

The diagnosis is confirmed with a liver biopsy. The reports say liver biopsy is compulsory for diagnosis and that an adequate sample containing at least 10 portal tracts is needed, with ductopenia defined as loss of bile ducts in more than 50% of the small portal tracts. Blood tests for autoimmune hepatitis, primary biliary cholangitis and viral hepatitis, and a careful search for lymphoma or other cancers, are part of the work-up.

Because the condition is rare and no standard protocol exists, a published review recommends that it be managed at a tertiary liver referral centre.

There is no single treatment. The report states that management primarily involves removal of the offending medicine, or treating the causative autoimmune disease or malignancy. If the trigger is a drug, stopping it is the key step, although improvement can take months because the ducts need time to regenerate.

Ursodeoxycholic acid, which the report describes as having choleretic, anti-inflammatory, immune-modulating and cytoprotective properties, is widely used and has been shown to be beneficial in some patients. The NHS lists ursodeoxycholic acid among the current treatments for primary biliary cholangitis. Case reports describe the use of corticosteroids in some people, and medicines can also be used to relieve itching.

In severe cases, and in people with cirrhosis, liver transplantation may be an option, as the report states. Because the evidence base is made up mainly of case reports and small series, decisions are individual and made by a hepatology team.

The prognosis is variable. The report explains that it depends on the balance between bile duct cell loss and regeneration. In people with unrelenting injury, irreversible duct loss and secondary biliary cirrhosis may follow, whereas in others the insult is removed and clinical recovery occurs over months to years. People whose VBDS followed a drug reaction or a treatable cancer have the best chance of improvement.

The NHS notes that, in related liver disease, cirrhosis and liver failure are the most serious consequences, and that a liver transplant is occasionally needed if the liver is severely damaged.

See a GP urgently, or use NHS 111, if your skin or the whites of your eyes turn yellow, particularly with itching, dark urine or pale stools. The NHS advises asking for an urgent GP appointment or getting help from NHS 111 in this situation.

Call 999 or go to A&E if jaundice is accompanied by confusion or drowsiness, vomiting blood, black stools, severe abdominal pain, or a high temperature with shaking chills, which can indicate infection or advanced liver failure.

There is no NHS patient page for vanishing bile duct syndrome and no UK charity guide that covers it directly at the time of writing. The statements on this page about the condition come from published case reports and reviews, which are international, so they should be treated as background rather than as UK guidance. NHS pages are cited only for general information on jaundice and bile duct disease. Your hepatologist is the right person to explain how this applies to you.